Charles Sawyers

Charles Sawyers has been a member of the Board of Directors since 2013. He qualifies as an independent Non-Executive Director. He is a member of the Research & Development Committee and the Governance, Nomination and Corporate Responsibilities Committee.

In the United States Sawyers is chair of the Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center, professor of medicine and of cell and developmental biology at the Weill Cornell Graduate School of Medical Sciences, and an investigator at the Howard Hughes Medical Institute. He serves on US President Barack Obama’s National Cancer Advisory Board and is past president of the American Association of Cancer Research and former president of the American Society for Clinical Investigation. He also is a member of the US National Academy of Sciences and Institute of Medicine.

Sawyers received his M.D. from the Johns Hopkins School of Medicine in the United States, and worked at the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles, for nearly 18 years before joining Memorial SloanKettering in 2006. An internationally acclaimed cancer researcher, he co-developed the Novartis cancer drug Gleevec/Glivec, and has received numerous honors and awards, including the LaskerDeBakey Clinical Medical Research Award in 2009.

Sawyers is a member of the Scientific Advisory Board of Agios Pharmaceuticals, Inc. in the United States.

Charles Sawyers is the Member of the Scientific Advisory Board at Blueprint Medicines, based in New York, New York, United States, North America. With a background in Biotechnology, Charles Sawyers has a rich history of leadership and innovation. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.